8-K: Predictive Oncology Grants Executive RSUs

Predictive Oncology Inc. awarded restricted stock units to its CEO and Interim CFO, vesting October 31, 2025, under its 2024 Equity Incentive Plan.

Summary

• Predictive Oncology Inc. (POAI) granted Restricted Stock Units (RSUs) to its Chief Executive Officer, Raymond F. Vennare, and Interim Chief Financial Officer, Josh Blacher.
• Raymond F. Vennare received 124,959 RSUs.
• Josh Blacher received 97,000 RSUs.
• Each RSU represents the right to receive one share of the company's common stock upon vesting.
• The RSUs will vest in full on October 31, 2025, contingent upon the executives' continued service through that date.
• These grants were made under the company's 2024 Equity Incentive Plan.
• The Board of Directors approved a form of Restricted Stock Unit Award Agreement on September 9, 2025, following a recommendation from the Compensation Committee.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While routine, these grants are a positive step for executive retention and alignment of interests, without indicating any immediate negative financial implications beyond standard dilution.

Positives

• The RSU grants align the interests of key executives (CEO and Interim CFO) with those of shareholders, as their compensation is tied to future stock performance.
• The vesting schedule, contingent on continued service, serves as an incentive for executive retention.
• Utilizing the 2024 Equity Incentive Plan demonstrates a structured approach to executive compensation.

Negatives

• The issuance of shares upon RSU vesting will result in a degree of dilution for existing shareholders, although the specific impact depends on the total outstanding shares and market capitalization.

Risks

• Unvested Restricted Stock Units will be forfeited if the grantee's employment or service terminates prior to the vesting date, except in cases of termination by the Company without Cause or required resignation from the Board for reasons other than Cause.
• Grantees are responsible for federal, state, local, or foreign tax withholding obligations upon vesting and settlement, which can be satisfied by withholding shares or remitting cash.
• Potential implications under Section 409A of the Code if the award does not qualify for exemption or comply with its requirements, potentially leading to additional taxation for the grantee.

Future Outlook

The RSUs are scheduled to vest in full on October 31, 2025, provided the executives remain in service. Following vesting, shares of common stock will be issued to the grantees within 30 days.

Management Comments

• The Board of Directors, upon the recommendation of the Compensation Committee, determined that it was appropriate to award restricted stock units as a form of compensation for employees, consultants, and directors.

Industry Context

The granting of Restricted Stock Units (RSUs) is a common practice in the biotechnology and technology sectors for executive compensation. It serves to attract, retain, and motivate key personnel by aligning their long-term financial interests with the company's performance and shareholder value. This practice is particularly prevalent in growth-oriented companies like those in oncology research, where long-term commitment is crucial.

Comparison to Industry Standards

• RSU grants are a standard component of executive compensation packages across various industries, including biotech, for their effectiveness in promoting long-term retention and performance alignment.
• The vesting schedule, contingent on continued service, is a typical structure designed to incentivize executives to remain with the company.
• The use of an existing equity incentive plan (2024 Equity Incentive Plan) for these grants is a common and transparent method for managing equity-based compensation.

Corporate Governance

Related Party Transactions

• The RSU grants to the Chief Executive Officer and Interim Chief Financial Officer represent compensation to related parties, approved by the Board of Directors upon recommendation of the Compensation Committee.

Stakeholder Impact

• Shareholders: Potential for future dilution upon RSU vesting, but also benefit from enhanced executive retention and alignment of interests.
• Executives (Raymond F. Vennare, Josh Blacher): Receive equity-based compensation, incentivizing long-term performance and commitment to the company.

Next Steps

• The RSUs will vest on October 31, 2025, subject to continued service.
• Shares of common stock will be issued to the grantees no later than 30 days following the vesting date.

Key Dates

Recommendation

This filing details routine executive compensation through RSU grants, which is a standard corporate action aimed at retaining key talent and aligning management incentives with shareholder value. It does not present new information that would fundamentally alter the company's financial outlook or operational strategy, nor does it indicate any significant positive or negative catalysts. Therefore, a 'hold' recommendation is appropriate as it maintains current positions based on existing fundamentals, awaiting more impactful news.

Keywords

Predictive Oncology, POAI, Restricted Stock Units, RSU, Executive Compensation, Equity Incentive Plan, Corporate Governance, NASDAQ, Biotech, Oncology